For decades, cyclosporin A has served medicine as a tool for quieting the immune system — yet it has long harbored a paradox, demonstrating antiviral properties that seemed to contradict its very purpose. Researchers have now traced this contradiction to its cellular roots, revealing that the drug simultaneously disrupts mitochondrial architecture and impairs the cell's own housekeeping machinery, allowing fragments of double-stranded RNA to accumulate and trigger a natural antiviral alarm system known as the RIG-I pathway. The discovery, emerging from studies of human airway cells and enginee
Cyclosporin A's antiviral mechanism revealed through RIG-I pathway activation
Cellular chaos that triggers antiviral defense
Mark
So cyclosporin A is an old drug. Why would anyone think to test it against viruses in the first place?
Mimi
It's been used in transplant patients for decades, and clinicians noticed it seemed to have some antiviral activity. But the mechanism was a black box. This study maps the actual pathway.
Luke
Right, but I want to be careful here. The antiviral effect was shown in cell culture and in mice. Has this been tested in actual infected humans taking the drug?
Mimi
Not in this paper. This is mechanistic work—explaining how the drug works at the cellular level. Clinical translation would be a separate question.
Mark
The mitochondrial remodeling—is that damage, or is it a functional adaptation?
Mimi
That's genuinely unclear from the data. The cristae change shape, the mitochondria fragment. Whether that's the cell deliberately restructuring or the cell being harmed is not resolved.
Luke
And the autophagy impairment—when you block autophagy, you're generally blocking a protective process. So is cyclosporin A helping the cell or hurting it?
Mimi
It's doing both. It's impairing a cleanup process, which normally would be bad. But in this case, that impairment allows dsRNA to accumulate, which triggers antiviral defenses. It's a side effect that happens to be useful against viruses.
Mark
The Torin-1 experiment is clever—it reverses the whole cascade. Does that mean Torin-1 would block the antiviral effect?
Mimi
Yes. If you gave both drugs together, you'd lose the antiviral benefit. But Torin-1 alone doesn't induce interferon, so you're not trading one effect for another.
Luke
One thing I notice: all the cell culture work is in epithelial cells from the lung or cervix. Is there any reason to think this pathway would work the same way in other tissues?
Mimi
The researchers did test it in primary human bronchial cells from multiple donors, which is more physiologically relevant. But you're right—we don't know if liver cells or immune cells would respond the same way.
Mark
If this were to be developed as a therapy, what would the challenge be?
Mimi
Cyclosporin A is already immunosuppressive. Using it as an antiviral would mean suppressing the immune system while trying to fight infection. You'd need to find a way to get the antiviral benefit without the immunosuppression.
Luke
And that's a big if. The paper shows the mechanism works in cells and in mouse models. But whether you could actually use this clinically, and whether the benefit would outweigh the risks, is still entirely open.
Le Pouls
- A drug trusted for decades to suppress immunity has been quietly activating antiviral defenses through a mechanism no one fully understood — until now.
- Cyclosporin A throws mitochondria into structural disarray and simultaneously jams the cellular recycling system, causing double-stranded RNA to pile up where it does not belong.
- That accumulated RNA triggers RIG-I, a molecular sentinel that sounds the interferon alarm — and when RIG-I is genetically removed, the drug's antiviral power vanishes entirely.
- Restoring autophagy with a second drug dismantles the entire chain reaction, confirming that the interplay of mitochondrial chaos and blocked cleanup is the true engine of the effect.
- The findings land as both a mechanistic resolution to a long-standing paradox and a potential blueprint for designing broad-spectrum antivirals ahead of the next pandemic.
For decades, cyclosporin A has served medicine as a tool for quieting the immune system — yet it has long harbored a paradox, demonstrating antiviral properties that seemed to contradict its very purpose. Researchers have now traced this contradiction to its cellular roots, revealing that the drug simultaneously disrupts mitochondrial architecture and impairs the cell's own housekeeping machinery, allowing fragments of double-stranded RNA to accumulate and trigger a natural antiviral alarm system known as the RIG-I pathway. The discovery, emerging from studies of human airway cells and engineered mice, reframes a familiar drug as an unlikely teacher about how the body's defenses can be awakened — and raises the possibility that this mechanism could inform how humanity prepares for future viral threats.
Cyclosporin A has been a clinical workhorse for decades, prescribed to prevent organ rejection by dampening immune responses. Yet researchers kept noticing something that didn't fit: the drug also fights viruses, and across a surprisingly broad range of them. The question of how has now been answered, and the mechanism is stranger and more intricate than expected.
When bronchial epithelial cells — the frontline tissue of the airways — were exposed to cyclosporin A, they began producing interferon-lambda, a key immune signaling protein, in a dose-dependent fashion. The pattern mirrored the body's natural antiviral sequence, where type III interferons mobilize first. The effect held across primary human cells from multiple donors, ruling out a laboratory artifact.
To find the molecular switch, researchers silenced RIG-I and its partner MAVS using genetic knockdown techniques. Without either protein, the drug could no longer induce interferon or the downstream genes that create an antiviral cellular state. In mice engineered to lack RIG-I entirely, cyclosporin A lost all ability to reduce SARS-CoV-2 infection — direct proof that RIG-I activation is the drug's essential mechanism.
RIG-I responds to double-stranded RNA in the cytoplasm, so the team looked for its source. Treated cells showed marked accumulation of dsRNA, including elevated mitochondrial RNA transcripts confirmed to be double-stranded. Electron microscopy revealed why: cyclosporin A was physically remodeling the mitochondria, collapsing their internal membrane folds from an ordered tubular network into fragmented, vesicular chaos.
But structural disruption alone wasn't the whole story. Autophagy — the process cells use to break down and recycle damaged material — normally clears dsRNA under healthy conditions. Cyclosporin A impairs this process, reducing autophagosome formation and causing the cleanup protein p62 to accumulate. With the recycling machinery blocked, the dsRNA produced by mitochondrial dysfunction was simply not being removed.
The causal chain was confirmed by introducing Torin-1, a drug that restores autophagy. It reduced dsRNA accumulation, lowered mitochondrial RNA levels, and reversed interferon induction entirely — while having no effect on its own. The sequence was also temporally ordered: mitochondrial RNA rose at six hours, interferon-lambda appeared at twelve, and downstream gene expression followed at eighteen.
What emerges is a portrait of a drug that paradoxically activates the very defenses it was designed to suppress — by disrupting mitochondria and blocking cellular cleanup simultaneously, allowing dsRNA to accumulate and sound an antiviral alarm. The findings offer both a mechanistic resolution to a long-standing clinical puzzle and a possible template for engineering new broad-spectrum antivirals.
Cyclosporin A is a drug that has been in clinical use for decades, primarily as an immunosuppressant to prevent organ rejection after transplants. But researchers have noticed something unexpected: it also appears to have antiviral properties, working against a broad range of viruses. The question has been how. A team of scientists has now traced the mechanism, and it turns out to involve a cascade of cellular disruptions that ultimately put cells into a defensive posture against infection.
When bronchial epithelial cells—the cells lining the airways—were exposed to cyclosporin A at concentrations of 10 and 25 micromolar, they began producing interferon-lambda, a type of immune signaling protein. The effect was dose-dependent: more drug, more interferon. The cells also released interferon-beta, though at much lower levels. This pattern mirrors the natural sequence of antiviral defense in epithelial tissue, where type III interferons like interferon-lambda typically mobilize first, followed by a weaker type I response. The researchers confirmed this effect in primary human bronchial cells isolated from three different donors, establishing that the phenomenon was not merely a quirk of laboratory cell lines.
The critical question was which molecular pathway the drug was activating. The team used genetic knockdown techniques to silence two key proteins: RIG-I and MAVS, which are part of a well-known antiviral signaling axis. When either protein was knocked down, cyclosporin A lost its ability to induce interferon-lambda and the downstream genes that establish an antiviral state. To test this more directly, researchers used mice genetically engineered to lack RIG-I entirely. In normal mouse airway cells, cyclosporin A reduced SARS-CoV-2 infection. In cells from RIG-I knockout mice, the drug had no antiviral effect whatsoever. This provided direct evidence that RIG-I activation is essential to the drug's mechanism.
But what triggers RIG-I in the first place? RIG-I is activated by the presence of double-stranded RNA in the cytoplasm. When the researchers examined cyclosporin A-treated cells under the microscope, they found marked accumulation of this dsRNA. They then looked specifically at mitochondrial RNA—two transcripts called ND5 and CyB—and found both were significantly elevated. When they treated the isolated RNA with RNase III, an enzyme that specifically degrades double-stranded RNA, the signal disappeared, confirming that the accumulated mitochondrial RNA was indeed double-stranded.
Transmission electron microscopy revealed why: cyclosporin A was remodeling the mitochondria themselves. The drug caused pronounced changes in the cristae—the internal folds of the mitochondrial membrane—shifting them from their normal tubular network structure to a disrupted, fragmented appearance with vesicular or network-like morphology. The mitochondria also changed in size and shape. This structural chaos appears to be the source of the accumulating dsRNA.
Yet there was another piece. Autophagy—the cellular process by which cells break down and recycle damaged components—normally degrades dsRNA under healthy conditions. The researchers found that cyclosporin A impairs autophagy. In cells engineered to express a fluorescent autophagy marker, cyclosporin A dose-dependently reduced the formation of autophagosomes, the vesicles that carry material to be degraded. Levels of p62, a protein that accumulates when autophagy is blocked, increased significantly in treated cells. This impaired autophagy meant that the dsRNA accumulating from mitochondrial dysfunction was not being cleared away.
To test whether restoring autophagy would reverse the effect, the researchers treated cells with both cyclosporin A and Torin-1, a drug that activates autophagy. Torin-1 reduced dsRNA accumulation, lowered mitochondrial RNA levels, and—critically—reversed the induction of interferon-lambda and the downstream interferon-stimulated genes. When Torin-1 was given alone, it had no effect on interferon production, confirming that it was specifically counteracting the cyclosporin A effect. The temporal sequence was clear: mitochondrial RNA levels rose first at six hours, interferon-lambda secretion appeared at twelve hours, and interferon-stimulated gene expression followed at eighteen hours. This ordered progression suggested a causal chain.
The picture that emerges is of a drug that simultaneously disrupts mitochondrial architecture and blocks the cellular cleanup machinery, allowing double-stranded RNA to accumulate in the cytoplasm. That dsRNA activates RIG-I, which triggers interferon-lambda production and a cascade of antiviral genes that establish a cellular state hostile to viral replication. The drug's broad-spectrum antiviral activity—demonstrated here against SARS-CoV-2 and previously against other viruses—appears to flow from this convergence of mitochondrial remodeling, dsRNA accumulation, and autophagy impairment. The findings offer a mechanistic explanation for why a drug designed to suppress immunity in one context can paradoxically activate antiviral defenses in another, and they suggest potential avenues for developing new antivirals based on similar principles.
Citations marquantes
The antiviral activity of cyclosporin A is partially driven by converging cellular processes involving mitochondrial remodeling, dsRNA accumulation, and impaired autophagy, which collectively activate the RIG-I/interferon-lambda/interferon-stimulated gene axis.— Study findings
Envie de l'histoire complète ?
Lire l'original sur Nature ↗
Weather & Disasters